16 research outputs found

    Increased deep sleep in a medication-free, detoxified female offender with schizophrenia, alcoholism and a history of attempted homicide: Case report

    Get PDF
    BACKGROUND: Psychiatric sleep research has attempted to identify diagnostically sensitive and specific sleep patterns associated with particular disorders. Both schizophrenia and alcoholism are typically characterized by a severe sleep disturbance associated with decreased amounts of slow wave sleep, the physiologically significant, refreshing part of the sleep. Antisocial behaviour with severe aggression, on the contrary, has been reported to associate with increased deep sleep reflecting either specific brain pathology or a delay in the normal development of sleep patterns. The authors are not aware of previous sleep studies in patients with both schizophrenia and antisocial personality disorder. CASE PRESENTATION: The aim of the present case-study was to characterize the sleep architecture of a violent, medication-free and detoxified female offender with schizophrenia, alcoholism and features of antisocial personality disorder using polysomnography. The controls consisted of three healthy, age-matched women with no history of physical violence. The offender's sleep architecture was otherwise very typical for patients with schizophrenia and/or alcoholism, but an extremely high amount of deep sleep was observed in her sleep recording. CONCLUSIONS: The finding strengthens the view that severe aggression is related to an abnormal sleep pattern with increased deep sleep. The authors were able to observe this phenomenon in an antisocially behaving, violent female offender with schizophrenia and alcohol dependence, the latter disorders previously reported to be associated with low levels of slow wave sleep. New studies are, however, needed to confirm and explain this preliminary finding

    Ultraviolet Irradiation Doses for Coronavirus Inactivation -Review and Analysis of Coronavirus Photo Inactivation Studies

    Full text link
    Background: To slow the increasing global spread of the SARS-CoV-2 virus, appropriate disinfection techniques are required. Ultraviolet radianon (UV) has a well-known antiviral effect. But measurements on the radiation dose necessary to inactivate SARS-CoV-2 have not been pub- lished so far. Methods: Coronavirus inactivation experiments with ultraviolet light performed in the past were evaluated to determine the UV radiation dose required for a 90% virus reduction. This analysis is based on the fact that all coronaviruses have a similar structure and similar RNA strand length. Results: The available data reveals large variations, which are apparently not caused by the coronaviruses but by the experimental conditions selected. If these are excluded as far as possible, it appears that coronaviruses are very UV sensitive. The upper limit determined for the log-reduction dose (90% reduction) is approximately 10.6 mJ/cm2 (median), while the true value is  probably only 3.7 mJ/cm2 (median). Conclusion: Since coronaviruses do not differ structurally to any great exent, the SARS-CoV-2 virus – as well as possible future mutations – will very likely be highly UV sensitive, so that common UV disinfection procedures will inactivate the new SARS-CoV-2 virus without any further modification

    COVID‐19 prevalence among health‐care workers of Gastroenterology department: An audit from a tertiary‐care hospital in India

    No full text
    Abstract Background and Aim In the present coronavirus disease‐19 (COVID‐19) era, health‐care workers (HCWs) warrant special attention because of their higher risk and potential to transmit the disease. Gastroenterology services include emergency and critical care along with the endoscopy procedures, which have aerosol‐generating potential. This study was aimed at auditing the COVID‐19 impact on HCWs working in the Gastroenterology department of our hospital. Methods The COVID‐19 status of 117 HCWs was collected using either polymerase chain reaction (PCR) or Immunoglobulin G (IgG) seroassay. COVID‐19 positivity was correlated with demographic characteristics, job profile, area of work, and medical history. Results Thirty‐eight HCWs (32.48%) showed evidence of COVID‐19 using PCR (23.93%) or only IgG assay (8.55%). Endoscopy technicians (68.75%) exhibited significantly higher (P = 0.003) COVID‐19 incidence compared to doctors (20.69%). Those working in the critical care units exhibited a trend toward higher COVID‐19 incidence (42.86%). None of the six HCWs who received adequate hydroxychloroquine prophylaxis developed evidence of COVID‐19. All the HCWs with COVID‐19 disease recovered. However, there was a considerable loss of “man‐days.” Conclusions In our setting, we observed a high COVID‐19 risk for HCWs working in the Gastroenterology department, with the highest risk among the endoscopy technicians. A more stringent triaging and pretesting of patients, as well as HCWs, might decrease the risk of COVID‐19. Further multicenter studies are needed to evaluate the risk and related parameters

    Solution characteristics and thermorheology of Prosopis africana seed polysaccharide

    Get PDF
    Of about forty four species of the Prosopis family known, only Prosopis africana is indigenous to Africa. We have isolated the polysaccharide constituent of P.rosopisafricana seed and studied its solution properties. The polysaccharide had a weight-average molecular weight of 1.72 × 106 g/mol and intrinsic viscosity of 11.6 dL/g. The effect of concentration and temperature on the polysaccharide viscosity and microstructure were investigated under steady and dynamic shear. The polysaccharide showed typical shear thinning characteristics and the critical angular frequency at the G-crossover points (G′ = G″) was concentration and temperature dependent and shifted to lower frequencies at higher polysaccharide concentrations. The onset of polymer overlap occurred at a critical concentration, c* = 0.186 g/dL with slope of 1.4 below and 4.4 above the point of polymer overlap concentration. The rheological behavior was studied as a function of temperature and the activation energy for viscous flow of 2% solution of the polysaccharide was calculated to be 24.3 kJ/mol. The rheological properties were shown to be similar to guar gum and hence it has potential use as a thickener in foods

    Rectal INdomethacin, oral TacROlimus, or their combination for the prevention of post-ERCP pancreatitis (INTRO Trial): Protocol for a randomized, controlled, double-blinded trial.

    No full text
    BACKGROUND: Acute pancreatitis remains the most common and morbid complication of endoscopic retrograde cholangiopancreatography (ERCP). The use of rectal indomethacin and pancreatic duct stenting has been shown to reduce the incidence and severity of post-ERCP pancreatitis (PEP), but these interventions have limitations. Recent clinical and translational evidence suggests a role for calcineurin inhibitors in the prevention of pancreatitis, with multiple retrospective case series showing a reduction in PEP rates in tacrolimus users. METHODS: The INTRO trial is a multicenter, international, randomized, double-blinded, controlled trial. A total of 4,874 patients undergoing ERCP will be randomized to receive either oral tacrolimus (5 mg) or oral placebo 1-2 h before ERCP, and followed for 30 days post-procedure. Blood and pancreatic aspirate samples will also be collected in a subset of patients to quantify tacrolimus levels. The primary outcome of the study is the incidence of PEP. Secondary endpoints include the severity of PEP, ERCP-related complications, adverse drug events, length of hospital stay, cost-effectiveness, and the pharmacokinetics, pharmacodynamics, and pharmacogenomics of tacrolimus immune modulation in the pancreas. CONCLUSIONS: The INTRO trial will assess the role of calcineurin inhibitors in PEP prophylaxis and develop a foundation for the clinical optimization of this therapeutic strategy from a pharmacologic and economic standpoint. With this clinical trial, we hope to demonstrate a novel approach to PEP prophylaxis using a widely available and well-characterized class of drugs. TRIAL REGISTRATION: NCT05252754, registered on February 14, 2022
    corecore